8 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using lenvatinib mesylate in the NHS in England for patients with liver cancer.

Lenvatinib mesylate is not recommended within its anticipated marketing authorisation for use by adults with untreated, advanced, unresectable hepatocellular carcinoma.

The cost-effectiveness estimates for lenvatinib mesylate compared with sorafenib tosylate are uncertain and there is no estimate that can be considered to be the most plausible. Most estimates that contained plausible assumptions are higher than the range normally considered to be an acceptable use of NHS resources. Also, lenvatinib mesylate does not meet NICE’s criteria to be considered a life-extending treatment at the end of life.

Read NICE Appraisal Consultation Document for lenvatinib mesylate